Cargando…
Mutational signatures in squamous cell carcinoma of the lung
BACKGROUND: Tumor mutational burden (TMB) has been identified as one of the predictors for the response to anti-programmed cell death-1 (anti-PD-1) antibody therapy and reported to correlate with smoking history in lung adenocarcinoma. However, in squamous cell carcinoma of the lung, the association...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947495/ https://www.ncbi.nlm.nih.gov/pubmed/33717580 http://dx.doi.org/10.21037/jtd-20-2602 |
_version_ | 1783663240934326272 |
---|---|
author | Osoegawa, Atsushi Takada, Kazuki Okamoto, Tatsuro Sato, Seijiro Nagahashi, Masayuki Tagawa, Tetsuzo Tsuchida, Masanori Oki, Eiji Okuda, Shujiro Wakai, Toshifumi Mori, Masaki |
author_facet | Osoegawa, Atsushi Takada, Kazuki Okamoto, Tatsuro Sato, Seijiro Nagahashi, Masayuki Tagawa, Tetsuzo Tsuchida, Masanori Oki, Eiji Okuda, Shujiro Wakai, Toshifumi Mori, Masaki |
author_sort | Osoegawa, Atsushi |
collection | PubMed |
description | BACKGROUND: Tumor mutational burden (TMB) has been identified as one of the predictors for the response to anti-programmed cell death-1 (anti-PD-1) antibody therapy and reported to correlate with smoking history in lung adenocarcinoma. However, in squamous cell carcinoma of the lung, the association between TMB and clinicopathological background factors, such as smoking history, has not been reported, including in our previous study. The mutational signature is a tool to identify the mutagens that are contributing to the mutational spectrum of a tumor by investigating the pattern of DNA changes. Here, we analyzed the mutational signature in lung squamous cell carcinoma to identify mutagens affecting the TMB. METHODS: Seven representative mutational signatures including signature 7 (SI7) [ultraviolet (UV)-related], SI4 (smoking), SI6/15 [mismatch repair (MMR)], SI2/13 [apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)], and SI5 (clock-like) were analyzed in Japanese patients with lung squamous cell carcinoma (n=67) using data generated by next-generation sequencing consisting of a 415-gene panel. The relationships between signatures and clinico-pathological data including TMB and programmed death-ligand 1 (PD-L1) expression were analyzed. RESULTS: Although the reconstructed mutational counts were small with targeted sequencing (median: 30.1, range: 13.3–98.7), the distributions of signatures were comparable among samples, with 56 cases containing more than four signatures. The smoking-related SI4 was found in 45 cases and was significantly related with pack-year index (PYI) (P=0.026). The reconstructed mutation counts were highly correlated with SI4 (r=0.51, P<0.0001), whereas the correlation was weak with SI6/15 (MMR-related) and SI2/13 (APOBEC-related). There was no mutational signature related with PD-L1 expression. Some patients exhibited unique signatures; the patient with the highest mutational counts had a MMR signature, and another patient with a prominent UV signature had occupational exposure to UV, as he was employed as a neon sign engineer. CONCLUSIONS: Mutational signatures can predict the cause of lung squamous cell carcinoma. Tobacco smoking is the mutagen most related with TMB. |
format | Online Article Text |
id | pubmed-7947495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-79474952021-03-12 Mutational signatures in squamous cell carcinoma of the lung Osoegawa, Atsushi Takada, Kazuki Okamoto, Tatsuro Sato, Seijiro Nagahashi, Masayuki Tagawa, Tetsuzo Tsuchida, Masanori Oki, Eiji Okuda, Shujiro Wakai, Toshifumi Mori, Masaki J Thorac Dis Original Article BACKGROUND: Tumor mutational burden (TMB) has been identified as one of the predictors for the response to anti-programmed cell death-1 (anti-PD-1) antibody therapy and reported to correlate with smoking history in lung adenocarcinoma. However, in squamous cell carcinoma of the lung, the association between TMB and clinicopathological background factors, such as smoking history, has not been reported, including in our previous study. The mutational signature is a tool to identify the mutagens that are contributing to the mutational spectrum of a tumor by investigating the pattern of DNA changes. Here, we analyzed the mutational signature in lung squamous cell carcinoma to identify mutagens affecting the TMB. METHODS: Seven representative mutational signatures including signature 7 (SI7) [ultraviolet (UV)-related], SI4 (smoking), SI6/15 [mismatch repair (MMR)], SI2/13 [apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)], and SI5 (clock-like) were analyzed in Japanese patients with lung squamous cell carcinoma (n=67) using data generated by next-generation sequencing consisting of a 415-gene panel. The relationships between signatures and clinico-pathological data including TMB and programmed death-ligand 1 (PD-L1) expression were analyzed. RESULTS: Although the reconstructed mutational counts were small with targeted sequencing (median: 30.1, range: 13.3–98.7), the distributions of signatures were comparable among samples, with 56 cases containing more than four signatures. The smoking-related SI4 was found in 45 cases and was significantly related with pack-year index (PYI) (P=0.026). The reconstructed mutation counts were highly correlated with SI4 (r=0.51, P<0.0001), whereas the correlation was weak with SI6/15 (MMR-related) and SI2/13 (APOBEC-related). There was no mutational signature related with PD-L1 expression. Some patients exhibited unique signatures; the patient with the highest mutational counts had a MMR signature, and another patient with a prominent UV signature had occupational exposure to UV, as he was employed as a neon sign engineer. CONCLUSIONS: Mutational signatures can predict the cause of lung squamous cell carcinoma. Tobacco smoking is the mutagen most related with TMB. AME Publishing Company 2021-02 /pmc/articles/PMC7947495/ /pubmed/33717580 http://dx.doi.org/10.21037/jtd-20-2602 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Osoegawa, Atsushi Takada, Kazuki Okamoto, Tatsuro Sato, Seijiro Nagahashi, Masayuki Tagawa, Tetsuzo Tsuchida, Masanori Oki, Eiji Okuda, Shujiro Wakai, Toshifumi Mori, Masaki Mutational signatures in squamous cell carcinoma of the lung |
title | Mutational signatures in squamous cell carcinoma of the lung |
title_full | Mutational signatures in squamous cell carcinoma of the lung |
title_fullStr | Mutational signatures in squamous cell carcinoma of the lung |
title_full_unstemmed | Mutational signatures in squamous cell carcinoma of the lung |
title_short | Mutational signatures in squamous cell carcinoma of the lung |
title_sort | mutational signatures in squamous cell carcinoma of the lung |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947495/ https://www.ncbi.nlm.nih.gov/pubmed/33717580 http://dx.doi.org/10.21037/jtd-20-2602 |
work_keys_str_mv | AT osoegawaatsushi mutationalsignaturesinsquamouscellcarcinomaofthelung AT takadakazuki mutationalsignaturesinsquamouscellcarcinomaofthelung AT okamototatsuro mutationalsignaturesinsquamouscellcarcinomaofthelung AT satoseijiro mutationalsignaturesinsquamouscellcarcinomaofthelung AT nagahashimasayuki mutationalsignaturesinsquamouscellcarcinomaofthelung AT tagawatetsuzo mutationalsignaturesinsquamouscellcarcinomaofthelung AT tsuchidamasanori mutationalsignaturesinsquamouscellcarcinomaofthelung AT okieiji mutationalsignaturesinsquamouscellcarcinomaofthelung AT okudashujiro mutationalsignaturesinsquamouscellcarcinomaofthelung AT wakaitoshifumi mutationalsignaturesinsquamouscellcarcinomaofthelung AT morimasaki mutationalsignaturesinsquamouscellcarcinomaofthelung |